First in Class Therapies to Prevent Epilepsy
We aim to develop treatments that prevent epilepsy after brain injuries such as head trauma, stroke and infection. Acquired seizures after such causes comprise at least 20% of all epilepsy, a disease that affects 1% of the world population. Our goals are to protect people from developing epilepsy and to spare them from its devastating consequences.
PrevEp is a US-based biotech company founded by world leaders in epilepsy research with decades of combined experience in the development of new therapies for epilepsy prevention. The founders combine deep expertise in basic science, drug development and clinical trials in epilepsy after CNS injury. The intimate collaboration between preclinical and clinical team members enables PrevEp to rapidly translate preclinical discoveries to clinical trials.
Epileptogenesis is a complex process that is unlikely to be arrested by a single drug. PrevEp leverages recent neuroscience discoveries in network pharmacology, and availability of proven and safe molecules to design combination therapies that target a multitude of epileptogenesis targets, in the earliest stages after brain injury. Our lead combinations are well-tolerated and have proven to block epileptogenesis in a predictive rodent model.
Pavel Klein, M.D. has >20 years clinical epilepsy research experience. Dr. Klein is PI of a recent NIH-funded clinical PTE prevention study, and current DoD PTE grant PI involving a consortium of 10 US and European trauma/epilepsy centers
Chief Development Officer co-founder
Detlev Boison, Ph.D. has >25 years translational epilepsy research experience. He is the PI of active antiepileptogenic drug discovery program, and identified a novel molecular target for antiepileptogenic therapy.
Vice President, Toxicology and Regulatory Affairs co-founder
Chris Rundfeldt, D.VM., Ph.D. has >30 years epilepsy and drug development research experience in pharmaceutical industry. Dr. Rundfeldt is a certified toxicologist and regulatory affairs with IPO experience.
Chief Scientific Officer co-founder
Wolfgang Löscher, D.VM., Ph.D. has >40 years translational epilepsy research experience. He is a highly decorated epilepsy scientist with extensive academic and industry experience in drug development.
Vice President, Biomarker Devel. co-founder
Alexander Rotenberg, M.D., Ph.D. has >15 years of translational and clinical epilepsy experience. He has been the PI of recent DoD and NIH PTE grants, and discovered an anti-epileptogenic target and related biomarker that are incorporated into the PrevEp portfolio and strategy.
Chief Business Officer
Alexander Kraus, Ph.D. is an international pharmaceutical executive with more than 20 years of experience in branded pharmaceutical industry. Dr. Kraus provides broad experience in R&D, business and portfolio development, strategic communications, and management competence in various therapeutic areas and indications
Company concept supported by leading epilepsy ambassadors
Jacqueline A. French, M.D.
Professor of Neurology and Director of clinical trials at NYU Langone‘s Comprehensive Epilepsy Center; Chief Scientific Officer, Epilepsy Foundation
Michael A. Rogawski, M.D., PhD.
Professor of Neurology and Pharmacology, Director of Institute for Neurotherapeutics, University of California, Davis
Elisabeth Garofalo, M.D.
Previous Senior VP, Novartis Pharmaceuticals
Annamaria Vezzani, Ph.D.
Professor of Neuroscience, Mario Negri Institute, Milan, Italy
Henrik Klitgaard, Ph.D.
Previous Vice President, Neurosciences Therapeutic Area, UCB Biopharma